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Abstract
Background: A benchmark of near-perfect adherence (≥95%) to antiretroviral therapy (ART) is 
often cited as necessary for HIV viral suppression. However, given newer, more effective ART 
medications, the threshold for viral suppression may be lower. We estimated the minimum ART 
adherence level necessary to achieve viral suppression.
Settings: The Patient-centered HIV Care Model demonstration project.
Methods: Adherence to ART was calculated using the proportion of days covered measure for 
the 365-day period before each viral load test result, and grouped into 5 categories (<50%, 50% to 
<80%, 80% to <85%, 85% to <90%, and ≥90%). Binomial regression analyses were conducted to 
determine factors associated with viral suppression (HIV RNA <200 copies/mL); demographics, 
proportion of days covered category, and ART regimen type were explanatory variables. 
Generalized estimating equations with an exchangeable working correlation matrix accounted for 
correlation within subjects. In addition, probit regression models were used to estimate adherence 
levels required to achieve viral suppression in 90% of HIV viral load tests.
Results: The adjusted odds of viral suppression did not differ between persons with an adherence 
level of 80% to <85% or 85% to <90% and those with an adherence level of ≥90%. In addition, 
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the overall estimated adherence level necessary to achieve viral suppression in 90% of viral load 
tests was 82% and varied by regimen type; integrase inhibitor- and nonnucleoside reverse 
transcriptase inhibitor-based regimens achieved 90% viral suppression with adherence levels of 
75% and 78%, respectively.
Conclusions: The ART adherence level necessary to reach HIV viral suppression may be lower 
than previously thought and may be regimen-dependent.
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INTRODUCTION
The ultimate goal of HIV care and treatment is to improve the duration and quality of life of 
persons with HIV. These goals are met through suppression of HIV RNA and restoration of 
immune function, which in turn decrease morbidity and mortality.1–4 Viral suppression has 
population level benefits as well, in that persons who are virally suppressed have effectively 
no risk of sexually transmitting HIV to uninfected partners.5 To become and remain 
virologically suppressed, persons with HIV must be adherent to appropriate antiretroviral 
therapy (ART) throughout their lifetime. Although adherence is important to the outcomes 
of therapy, patients face multiple barriers to consistent adherence including lack of access, 
treatment fatigue, stigma, and comorbid conditions.6,7
Given patients’ adherence barriers, potential history of nonadherence to therapy, and lifelong 
need for treatment, having a better understanding of what ART adherence level is necessary 
for viral suppression is valuable for clinicians when determining optimal antiretroviral 
(ARV) regimens for patients. Researchers have frequently set a benchmark for adherence at 
≥95%. This threshold is mostly derived from a study conducted between 1997 and 1999, of 
persons on unboosted protease inhibitor therapy, which found that persons with adherence 
levels ≥95% (measured using a microelectronic monitoring system) had less virologic failure 
and increased CD4 lymphocyte count when compared with persons with adherence <95%.8 
Other early studies showed similar results.9,10 Although 95% has long been considered the 
gold standard of adherence to ART, a lower adherence level of ≥90% has been set by the 
Pharmacy Quality Alliance.11 Given the enhanced pharmacokinetic profiles of newer ARV 
medications, even the lower adherence level of ≥90% may not be necessary to achieve HIV 
viral suppression.12 As such, we used data from a national demonstration project to estimate 
the minimum adherence level required for HIV viral suppression.
METHODS
Project Design and Participants
Data used for this analysis are from the Patient-centered HIV Care Model (PCHCM) 
demonstration project. This was a secondary analysis; the results are unrelated to the goals 
of the demonstration project. The PCHCM is described in detail elsewhere.13 In short, the 
PCHCM project partnered community-based HIV-specialty pharmacists with HIV medical 
providers and required the partnered pharmacists and medical providers to share patient 
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clinical information, identify therapy-related problems, and develop therapy-related action 
plans. The project provided services to 765 adults with HIV at 10 project sites (made up of 
≥1 medical clinic and ≥1 HIV-specialty retail pharmacy) throughout the United States from 
August 2014 to September 2016. Data collected for the PCHCM included, but were not 
limited to, prescription fulfillment data, HIV viral load test results, and participant 
demographics. Between 12 and 48 months of data were collected on each participant.
Independent Variable—Adherence to ART
Adherence to ART was calculated as the proportion of days covered (PDC). The PDC is a 
pharmacy claims-based metric that reflects the proportion of days for which a person has 
medication available during a measurement period. The ART PDC is calculated by dividing 
the number of days of ART coverage during the measurement period by the length of the 
measurement period; adjustments are made for fill days’ supply and for days with 
overlapping medication supply.14 ART coverage was defined as at least 3 ARV medication 
components (excluding cobicistat). Data were extracted from PCHCM pharmacy fulfillment 
records.
Adherence to ART was calculated for the 365-day period before each viral load test result, 
and was grouped into one of 5 PDC categories (<50%, 50% to <80%, 80% to <85%, 85% to 
<90%, and ≥90%). Adherence was calculated overall and by ARV regiment type. ARV 
regimens were grouped into 4 categories: (1) integrase inhibitor (INSTI)-based, (2) 
nonnucleoside reverse transcriptase inhibitor (NNRTI)-based, (3) protease inhibitor (PI)-
based (included both boosted and nonboosted regimens), and (4) “all other types” (all 
regimens not categorized as an INSTI-, NNRTI- or PI-based (eg, INSTI-two-NRTI-PI). The 
INSTI-, NNRTI-, and PI-based regimens each included one medication of the main 
component (eg, one INSTI medication) and 2 nucleoside reverse transcriptase inhibitors 
(NRTI) as the “backbone” of the therapy. Because a person could be on more than one 
regimen during the 365-day adherence measurement period, a primary regimen type was 
identified as the regimen that was used for the plurality of the measurement period.
Outcome Variable—HIV Viral Suppression
The dependent variable for the analysis was a dichotomous indicator of HIV viral 
suppression, defined as an HIV viral load of <200 HIV RNA copies/mL.15 The suppression 
value of <200 copies/mL was based on the U.S. Department of Health and Human Services 
recommended definition of virologic failure.1 Each viral load test result was included in the 
analysis if the test had a corresponding 365 days of ART fulfillment data before the test 
result (so that each viral load would have a corresponding PDC value). Each viral load test 
result with a corresponding PDC value was included in the analysis even when multiple viral 
load test results for the same participant had overlapping adherence windows (ie, a person 
had more than one viral load test within a 365-day adherence measurement period). 
Laboratory test result data were abstracted from project clinic records.
Statistical Analysis
Bivariate and multivariable binomial regression analyses were used to determine factors 
associated with viral suppression. Generalized estimating equations with an exchangeable 
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working correlation matrix were used to account for correlation within subjects. Odds ratios 
with 95% confidence intervals (CI) were calculated, separately, for each demographic factor 
(age, sex, race/ethnicity, and insurance type), categorical PDC level, and ARV regimen type. 
All demographic variables were considered for inclusion in the final multivariable model. 
The final model was determined using forward stepwise variable selection, and included all 
factors that were significant at the 0.05 level. In addition, probit regression models were 
used to create dose-response curves and to estimate the adherence level required to achieve 
viral suppression in 90% of HIV viral load tests, overall and by regimen category. All data 
were analyzed using SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS
Of the 765 participants, 570 had ≥1 HIV viral load test result with a corresponding PDC 
value and were, therefore, eligible for the analysis. More than half of these individuals were 
aged ≥50 years (53%), non-black or of unknown race/ ethnicity (59%), men (78%), and 
nonprivately insured (85%) (Table 1). Each person’s record contributed a median of 4 viral 
load test results (interquartile range [IQR]: 2–6) to the analysis. More than half (67%) of the 
2427 viral load test results, included in the analysis, coincided with a PDC ≥90% in the 
previous 365 days and most (90%) were <200 copies/mL. The primary regimen types were: 
INSTI-based (31%), “all other” (30%), NNRTI-based (21%), and PI-based (18%) (Table 1).
Bivariate and Multivariable Binomial Regression
Results from the bivariate and multivariable analyses are shown in Table 2. After adjusting 
for all covariates and within person correlations, persons aged ≥50 years (adjusted odds ratio 
[aOR] 2.33; 95% CI: 1.70 to 3.21), men (aOR 1.49; 1.07, 2.08), and privately insured 
persons (aOR 1.77; 1.04, 3.00) had greater odds of being virally suppressed compared with 
persons aged <50 years, women, and nonprivately insured persons, respectively. Non-
Hispanic black persons had lower odds of suppression (aOR 0.46; 0.33, 0.64) compared with 
all other races and ethnicities combined (including persons with unknown race/ethnicity).
There were no significant differences in the adjusted odds of viral suppression for persons 
with a PDC of 80% to <85% or 85% to <90% compared with that of persons with a PDC of 
≥90%. Persons within the “all other” regimen category had lower adjusted odds (aOR 0.51; 
0.34, 0.77) of suppression when compared with persons on PI-based regimens. Persons on 
INSTI- or NNRTI-based regimens did not have significantly different adjusted odds of 
suppression when compared with persons on PI-based regimens.
Probit Regression
Results from the probit regression model are presented in Figure 1. Among all regimen 
types, the adherence level required to achieve viral suppression in 90% of HIV viral load 
tests was 82% (Fig. 1A). The adherence level required to achieve viral suppression in 90% 
of tests varied depending on ARV regimen type: 75% for INSTI-based, 78% for NNRTI-
based, 87% for PI-based, and 99% for “all other” regimen types (Fig. 1B).
Byrd et al. Page 4
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2020 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
DISCUSSION
After adjusting for demographic factors, within-person correlation, and ARV regimen type, 
we found that the odds of viral suppression did not differ significantly between persons with 
adherence levels between 80% and <85% or 85% to <90% and those with the Pharmacy 
Quality Alliance recommended adherence level of ≥90%. In addition, the overall estimated 
adherence level necessary to achieve viral suppression in 90% of HIV viral load tests was 
82% and varied by regimen type; 90% of viral load tests associated with INSTI-based and 
NNRTI-based regimens were virally suppressed at adherence levels of 75% and 78%, 
respectively. These results indicate that the adherence level necessary to reach viral 
suppression may be lower than previously believed and may be more in line with the 80% 
adherence threshold often applied for other chronic diseases (eg, hypertension, 
hypercholesterolemia).16
Previous studies on the adherence threshold required for viral suppression are heterogeneous 
and often differ in the outcome of interest (eg, HIV RNA level of <50, <200, or <400 copies/
mL), the adherence measure (eg, self-report, pill counts, medication possession ratios, and 
proportion of days covered), and the threshold for failure (eg, 10% or 20% of persons not 
suppressed) which makes comparisons between this and other studies somewhat difficult.
17–22
 However, our finding of no significant difference in the adjusted odds of viral 
suppression with adherence between 80% and <85% or 85% to <90% and ≥90% is 
consistent with like studies.17–23 For example, a meta-analysis of 43 studies which evaluated 
adherence thresholds and virologic outcomes, found no significant difference in the pooled 
odds of virologic failure at adherence levels of ≥95% or ≥98%–100% and adherence levels 
of ≥80%–90%.21 Similarly, using adherence self-report from a cohort study of men who 
have sex with men, Viswanathan et al17 found that ≥80% of persons were virally suppressed 
(<50 copies/mL) at adherence levels between 80% and 84%.
Although the adjusted odds of suppression were not statistically different between either 
INSTI-based or NNRTI-based regimens when compared with PI-based regimens, PI-based 
regimens required a higher adherence level to achieve viral suppression. Although this 
analysis was not powered to evaluate differences between regimen types, the higher 
adherence threshold we observed for PI-based regimens, is similar to other studies.
18,20,22,24,25
 However, our analysis did not distinguish between boosted and unboosted PI-
based regimens, which might have accounted for some of the threshold differences. 
Regimens categorized as “all other” had lower adjusted odds of suppression and the highest 
adherence level necessary for viral suppression. The higher adherence level required for 
viral suppression with “all other” regimen types is not surprising given that this category 
includes regimens not considered adequate by treatment guidelines and because this 
category may represent non-standard or salvage regimens for persons who had previously 
failed therapy.1
When examining the study’s “All regimen types” dose-response curve, high proportions of 
viral load tests were suppressed even with adherence levels around 60%. This result is 
similar to that of Gordon et al19 who found a virologic failure rate (defined as 2 consecutive 
viral loads test results ≥200 copies/mL) for 3 first-line ARV regimens of approximately 20% 
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at adherence levels of roughly 60%. The modest adherence levels necessary for viral 
suppression, seen in this analysis, is reflective of the improved potency and efficacy of 
newer ARV medications.12
Non-Hispanic black persons, younger persons and women had lower odds of viral 
suppression even after adjustment for adherence level and regimen category; the reasons for 
this are unclear. However, achieving viral suppression is dependent on factors additional to 
adherence such as underlying drug resistance and drug–drug or drug–food interactions, 
which can affect effectiveness of therapy.26–28 This analysis was unable to account for these 
other determinants of viral suppression in any demographic group.
Although we estimate that an overall adherence level of 82% is necessary for viral 
suppression in 90% of viral load tests, with lower thresholds for INSTI- and NNRTI-based 
regimens, these results should be used with caution. In addition to the risk of virologic 
rebound, poor adherence is associated with development of drug resistance (which can 
potentially reduce future treatment options), systemic inflammation, and higher health care 
use and costs.21,22,29–34 In particular, drug resistance is more common with NNRTI-based 
regimens in the absence of viral suppression.29 Clinicians’ message to patients should, 
therefore, remain “every dose every day” and be accompanied by continuous adherence 
counseling and support.35 These results may be useful when considering patients’ adherence 
barriers and optimal ARV regimens for these patients. In addition, a PDC of ≥82% may be 
sufficient to indicate adequate adherence when measuring PDC levels in pharmacy claims or 
fulfillment data not linked to viral load test results.
The study results should be viewed in light of its limitations. First, the PDC is a proxy for 
adherence. The PDC measures the amount of time a person has medication available, not 
actual pill-taking behavior; therefore, adherence was likely overestimated. In addition, the 
PDC does not measure 2 other important facets of adherence: whether a person takes their 
medication according to the prescriber’s instruction or on the prescribed schedule. However, 
using pharmacy fulfillment data to calculate adherence has an advantage over some other 
methods (eg, self-report, pill counts, and electronic monitoring) that are potentially 
confounded by social desirability and recall bias or expense.36 For this analysis, accurate 
PDC measurement required a closed pharmacy system; adherence would be underestimated 
if persons filled ARV prescriptions outside of the project pharmacy network. This analysis 
did not take into account the amount of time a person was virally suppressed; therefore, the 
analysis did not account for the decreased risk of virologic failure after prolonged periods of 
viral suppression.37 In addition, the analysis did not account for time since treatment 
initiation. The analysis, therefore, did not account for potentially higher adherence needed to 
achieve viral suppression in the first year after treatment initiation. Finally, participants in 
the PCHCM demonstration project represented a convenience sample which limits 
generalizability.
These data indicate that overall HIV viral suppression can be achieved for 90% of HIV viral 
load tests with an estimated ART adherence level of 82%, which is similar to that applied to 
other chronic diseases. The adherence threshold varied by regimen type with both INSTI-
based and NNRTI-based regimens achieving viral suppression with even lower adherence 
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levels (75% and 78%, respectively), suggesting that some regimen types may be more 
forgiving of missed doses than others. These results are reflective of the improved potency 
and efficacy of newer ARV medications. Although this analysis found an adherence level 
necessary for viral suppression that was lower than the conventionally reported values of 
≥90% or ≥95%, clinicians should be encouraged to continue to advise patients to take all of 
their medications, as prescribed, to identify and address adherence barriers and to offer 
continuous adherence support.
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FIGURE 1. 
*PDC, proportion of days covered; † Φ is the cumulative distribution function for the 
standard normal distribution; ‡INSTI, integrase inhibitor; §NNRTI, nonnucleoside reverse 
transcriptase inhibitor; ‖PI, protease inhibitor; ¶INSTI-, NNRTI-, and PI-based regimens 
each included one medication of the main component and 2 nucleoside reverse transcriptase 
(NRTI) drugs as the “backbone” of the therapy; **includes all regimens not categorized as 
an INSTI-, NNRTI-, or PI-based. The horizontal dash lines represent the 90% benchmark for 
viral suppression and the dotted vertical lines represent the PDC level at which 90% of HIV 
viral load tests were suppressed (HIV RNA <200 copies/mL).
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TABLE 1.
Characteristics of Patients and Viral Load Tests Included in the Analysis, Patient-Centered HIV Care Model, 
2014–2016, United States
Characteristic Total
Patient characteristics, n = 570
Median age (years [IQR]) 49 (40–57)
Median no. of viral load tests (IQR) 4 (2–6)
Characteristic, n (%)
Age (yrs)
 <50 268 (47)
 ≥50 302 (53)
Race/Ethnicity
 Black, non-Hispanic 231 (41)
 All other/unknown 339 (59)
Sex
 Male 444 (78)
 Female 126 (22)
Medical insurance
 Private insurance 83 (15)
 Nonprivate insurance 487 (85)
Viral load test characteristics, n = 2427*
PDC category, n (%)
 <50% 202 (8)
 50% to <80% 277 (11)
 80% to <85% 162 (7)
 85% to <90% 173 (7)
 ≥90% 1613 (67)
Viral load test results, n (%)
 <200 copies/mL 2180 (90)
 ≥200 copies/mL 247 (10)
ARV regimen category, n (%)†
 INSTI-based 756 (31)
 NNRTI-based 513 (21)
 PI-Based 427 (18)
 All other‡ 731 (30)
  INSTI-NRTI(2)-PI§ 122 (17)
  INSTI -NNRTI-PI§ 79 (11)
  INSTI -PI§ 65 (9)
  INSTI -NNRTI-NRTI(2)§ 53 (7)
  NRTI(2)-PI(2)§ 43 (6)
  NNRTI-NRTI(2)-PI§ 41 (6)
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Characteristic Total
  INSTI -NNRTI-NRTI§ 40 (6)
*Viral load tests with PDC values and included in the analysis, including the coinciding PDC category, viral load test value, and the coinciding 
primary ARV regimen.
†
INSTI-, NNRTI-, and PI-based regimens each included one medication of the main component and 2 nucleoside reverse transcriptase inhibitors 
(NRTI) as the “backbone” of the therapy.
‡
“All other” category includes all regimens not categorized as an INSTI-, NNRTI-, or PI-based regimen.
§
The most common regimens within the “all other” category. The parentheses indicate the number of medication types within the regimen.
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TABLE 2.
Factors Associated With HIV Viral Suppression (HIV RNA Levels <200 Copies/mL), Patient-centered HIV 
Care Model, 2014–2016, United States
HIV RNA <200 copies/mL (n = 2427)
Bivariate OR (95% CI) P Multivariable aOR (95% CI) P
Age ≥50 yrs* 3.16 (2.09 to 4.78) <0.0001 2.33 (1.70 to 3.21) <0.0001
Black, non-Hispanic† 0.30 (0.20 to 0.44) <0.0001 0.46 (0.33 to 0.64) <0.0001
Males 2.51 (1.64 to 3.84) <0.0001 1.49 (1.07 to 2.08) 0.0174
Private insurance‡ 2.08 (1.05 to 4.15) 0.0364 1.77 (1.04 to 3.00) 0.0344
PDC level
 <50% 0.16 (0.10 to 0.25) <0.0001 0.16 (0.11 to 0.23) <0.0001
 50% to <80% 0.29 (0.20 to 0.43) <0.0001 0.30 (0.19 to 0.47) <0.0001
 80% to <85% 0.50 (0.32 to 0.76) 0.0013 0.49 (0.23 to 1.04) 0.0627
 85% to <90% 0.59 (0.37 to 0.93) 0.0228 0.96 (0.49 to 1.90) 0.9138
 ≥90% REF — REF —
ARV regimen category§
 INSTI-based 1.55 (0.94 to 2.54) 0.0832 1.38 (0.90 to 2.13) 0.1391
 NNRTI-based 1.52 (0.88 to 2.65) 0.1367 1.21 (0.75 to 1.94) 0.4342
 PI-Based REF — REF —
 All others 0.79 (0.48 to 1.31) 0.3598 0.51 (0.34 to 0.77) 0.0013
*
Persons aged ≥50 years were compared with persons aged <50 years.
†
Black, non-Hispanic persons were compared with persons of all other race/ethnicities and persons with unknown race/ethnicity combined.
‡
Persons with private insurance were compared with persons without private insurance.
§
INSTI-, NNRTI-, and PI-based regimens each included one medication of the main component and 2 nucleoside reverse transcriptase (NRTI) 
drugs as the “backbone” of the therapy.
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